This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yonekura, K. Articles by Yamada, Y. Search for Related Content PubMed PubMed Citation Articles by Yonekura, K. Articles by Yamada, Y.

UFT and Its Metabolites Inhibit the Angiogenesis Induced by Murine Renal Cell Carcinoma, as Determined by a Dorsal Air Sac Assay in Mice

Cancer Research Laboratory, Hanno Research Center, Taiho Pharmaceutical Co., Ltd., Saitama, 357 Japan

UFT, an anticancer agent that is composed of tegafur (FT) and uracil at a molar ratio of 1:4, is widely used in clinical practice in Japan to treat cancer patients requiring a long-term chemotherapy, and it is associated with few side effects, if any. In this study, we have evaluated the inhibitory effect of UFT against RENCA cell-induced angiogenesis by a dorsal air sac assay. Marked angiogenesis is induced by implantation of a chamber containing RENCA cells into mice. In this model, UFT showed a strong angiogenesis-inhibitory effect, whereas 5-fluorouracil (5-FU) and doxifluridine were less effective. Additional experiments revealed FT to be effective component of UFT; uracil remained ineffective in the inhibition of angiogenesis. Moreover, we have found that -hydroxybutyric acid and -butyrolactone, the metabolites of FT, possess a potent angiogenesis inhibitory effect that is amplified when the compounds are administered by a continuous infusion. This may reflect a transition in blood concentration of each metabolite resulting from the administration of UFT. Similar results were also obtained with respect to 5-FU. It was suggested that UFT has a stronger angiogenesis-inhibitory effect than did other fluorinated pyrimidines, partly due to its pharmacokinetic properties characterized by maintaining of higher and long-lasting blood levels of 5-FU and partly due the inhibitory effects derived from -hydroxybutyric acid and -butyrolactone, UFT-specific metabolites.

This article has been cited by other articles:

				T. Tsuzuki and Y. Kawakami Tumor angiogenesis suppression by {alpha}-eleostearic acid, a linolenic acid isomer with a conjugated triene system, via peroxisome proliferator-activated receptor {gamma} Carcinogenesis, April 1, 2008; 29(4): 797 - 806. [Abstract] [Full Text] [PDF]

				K. Nakagawa, A. Shibata, S. Yamashita, T. Tsuzuki, J. Kariya, S. Oikawa, and T. Miyazawa In Vivo Angiogenesis Is Suppressed by Unsaturated Vitamin E, Tocotrienol J. Nutr., August 1, 2007; 137(8): 1938 - 1943. [Abstract] [Full Text] [PDF]

				R. Munoz, S. Man, Y. Shaked, C. R. Lee, J. Wong, G. Francia, and R. S. Kerbel Highly Efficacious Nontoxic Preclinical Treatment for Advanced Metastatic Breast Cancer Using Combination Oral UFT-Cyclophosphamide Metronomic Chemotherapy. Cancer Res., April 1, 2006; 66(7): 3386 - 3391. [Abstract] [Full Text] [PDF]

				K. M.W. Pisters and T. Le Chevalier Adjuvant Chemotherapy in Completely Resected Non-Small-Cell Lung Cancer J. Clin. Oncol., May 10, 2005; 23(14): 3270 - 3278. [Abstract] [Full Text] [PDF]

				I. S. Woo, D. H. Moon, B. Y. Shim, M. A. Lee, J. H. Byun, K. W. Kim, J.-H. Kang, M. G. Choi, I.-S. Chung, Y. S. Hong, et al. A Phase II Study of Epirubicin, Cisplatin and Uracil-Tegafur for Advanced Gastric Carcinoma Jpn. J. Clin. Oncol., January 1, 2005; 35(1): 13 - 17. [Abstract] [Full Text] [PDF]

				M. Nakagawa, F. Tanaka, N. Tsubota, M. Ohta, M. Takao, H. Wada, and On behalf of the West Japan Study Group for Lung C A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)--the 4th study Ann. Onc., January 1, 2005; 16(1): 75 - 80. [Abstract] [Full Text] [PDF]

				H. Kato, Y. Ichinose, M. Ohta, E. Hata, N. Tsubota, H. Tada, Y. Watanabe, H. Wada, M. Tsuboi, N. Hamajima, et al. A Randomized Trial of Adjuvant Chemotherapy with Uracil-Tegafur for Adenocarcinoma of the Lung N. Engl. J. Med., April 22, 2004; 350(17): 1713 - 1721. [Abstract] [Full Text] [PDF]

				T. Kohno, H. Mizukami, M. Suzuki, Y. Saga, Y. Takei, M. Shimpo, T. Matsushita, T. Okada, Y. Hanazono, A. Kume, et al. Interleukin-10-mediated Inhibition of Angiogenesis and Tumor Growth in Mice Bearing VEGF-producing Ovarian Cancer Cancer Res., August 15, 2003; 63(16): 5091 - 5094. [Abstract] [Full Text] [PDF]

				M. Malet-Martino and R. Martino Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review Oncologist, August 1, 2002; 7(4): 288 - 323. [Abstract] [Full Text] [PDF]

				Y. Hasumi, H. Mizukami, M. Urabe, T. Kohno, K. Takeuchi, A. Kume, M. Momoeda, H. Yoshikawa, T. Tsuruo, M. Shibuya, et al. Soluble FLT-1 Expression Suppresses Carcinomatous Ascites in Nude Mice Bearing Ovarian Cancer Cancer Res., April 1, 2002; 62(7): 2019 - 2023. [Abstract] [Full Text] [PDF]

				H. Ishikura, K. Kondo, T. Miyoshi, H. Kinoshita, Y. Takahashi, H. Fujino, and Y. Monden Suppression of Mediastinal Metastasis by Uracil-Tegafur or cis-Diamminedichloroplatinum(II) Using a Lymphogenous Metastatic Model in a Human Lung Cancer Cell Line Clin. Cancer Res., December 1, 2001; 7(12): 4202 - 4208. [Abstract] [Full Text] [PDF]

				K. D. Miller, C. J. Sweeney, and G. W. Sledge Jr Redefining the Target: Chemotherapeutics as Antiangiogenics J. Clin. Oncol., February 15, 2001; 19(4): 1195 - 1206. [Abstract] [Full Text] [PDF]

				T. Browder, C. E. Butterfield, B. M. Kräling, B. Shi, B. Marshall, M. S. O’Reilly, and J. Folkman Antiangiogenic Scheduling of Chemotherapy Improves Efficacy against Experimental Drug-resistant Cancer Cancer Res., April 1, 2000; 60(7): 1878 - 1886. [Abstract] [Full Text]